Beaujon Hospital / Hôpital Beaujon


Hospital

Location:
Paris, France


Publications in cooperation with FAU scientists


Kelley, R.K., Gane, E., Assenat, E., Siebler, J., Galle, P.R., Merle, P.,... Giannelli, G. (2019). A Phase 2 Study of Galunisertib (TGF-beta 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 10. https://dx.doi.org/10.14309/ctg.0000000000000056
Klompmaker, S., Peters, N.A., Van Hilst, J., Bassi, C., Boggi, U., Busch, O.R.,... Roeyen, G. (2019). Outcomes and Risk Score for Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): An International Multicenter Analysis. Annals of Surgical Oncology, 26(3). https://dx.doi.org/10.1245/s10434-018-07101-0
Dromain, C., Pavel, M.E., Ruszniewski, P., Langley, A., Massien, C., Baudin, E., & Caplin, M.E. (2019). Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. BMC Cancer, 19(1). https://dx.doi.org/10.1186/s12885-018-5257-x
Lamarca, A., Ronot, M., Moall, S., Crona, J., Opalinska, M., Lopez, C.,... Dromain, C. (2019). Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study. In NEUROENDOCRINOLOGY (pp. 137-137). BASEL: KARGER.
Capdevila, J., Bodei, L., Davies, P., Gorbounova, V., Jensen, R.T., Knigge, U.P.,... Wiedenmann, B. (2019). Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms. Neuroendocrinology, 108(1), 18-25. https://dx.doi.org/10.1159/000493319
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2019). Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients’ Outcome in Neuroendocrine Tumors (NET)—The GREPONET Study. Oncologist. https://dx.doi.org/10.1634/theoncologist.2018-0672
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Yao, J.C., Yao, J.C., Fazio, N., Li, D., Pavel, M.E., Strosberg, J.,... Singh, S. (2018). ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment. (pp. 218-218).
Pavel, M.E., Cwikla, J., Wolin, E., Phan, A., Raderer, M., Sedlackova, E.,... Caplin, M. (2018). Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension. (pp. 310-310).
Wolin, E.M., Pavel, M.E., Cwikla, J.B., Phan, A.T., Raderer, M., Sedlackova, E.,... Caplin, M.E. (2018). Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study. (pp. 358-359).
Merola, E., Zandee, W., De Mestier, L., De Mestier, L., Klumpen, H.J., Geboes, K.P.,... Munir, A. (2018). Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference? (pp. 144-144).
Crona, J., Crona, J., Lamarca, A., Ronot, M., Opalinska, M., Lopez Lopez, C.,... Dromain, C. (2018). Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study. (pp. 171-171).
Lamarca, A., Crona, J., Ronot, M., Opalinska, M., Lopez Lopez, C., Pezzutti, D.,... Dromain, C. (2018). Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study. (pp. 178-178).
Cwikla, J.B., Wolin, E.M., Pavel, M.E., Phan, A.T., Raderer, M., Sedlackova, E.,... Caplin, M. (2017). Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension.
Rosendahl, J., Kirsten, H., Hegyi, E., Kovacs, P., Weiss, F.U., Laumen, H.,... Sahin-Toth, M. (2017). Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. Gut. https://dx.doi.org/10.1136/gutjnl-2017-314454

Last updated on 2016-06-06 at 13:38